{"slideshow_credits": null, "snippet": "Results from two studies of Eli Lilly\u2019s solanezumab suggested it may slow mental decline, but doctors said another study was probably necessary for federal approval.", "abstract": "Results from two studies of Eli Lilly\u2019s experimental Alzheimer's drug solanezumab suggest it may slow mental decline, but doctors say another study is probably necessary for federal approval.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "THE ASSOCIATED PRESS", "original": "By THE ASSOCIATED PRESS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/10/09/business/eli-lilly-drug-shows-promise-in-treating-mild-alzheimers.html", "lead_paragraph": "Results from two studies of Eli Lilly\u2019s solanezumab suggested it may slow mental decline, but doctors said another study was probably necessary for federal approval.", "headline": {"seo": "Eli Lilly Drug Shows Promise in Treating Mild Alzheimer\u2019s", "main": "Eli Lilly Drug Shows Promise in Treating Mild Alzheimer\u2019s", "print_headline": "Eli Lilly Drug Shows Promise In Treating Mild Alzheimer\u2019s"}, "_id": "507c4d8c95e998af71185cc3", "word_count": "343", "multimedia": [], "pub_date": "2012-10-09T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Alzheimer's Disease", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Eli Lilly and Company", "name": "organizations", "is_major": "Y", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}